Allogene Therapeutics Inc.

01/07/2024 | Press release | Distributed by Public on 01/07/2024 13:13

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema cel) as First[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.